News &
Media
-
Australia’s Neurotech Inks Cannabis Cultivation Partnership
View More: Australia’s Neurotech Inks Cannabis Cultivation PartnershipNeurotech International Limited (ASX:NTI) has established a strategic medical cannabis cultivation partnership with CannaPacific Limited.
-
Neurotech just started world’s first THC-less cannabis study in autistic children
View More: Neurotech just started world’s first THC-less cannabis study in autistic childrenThe Phase I/II clinical trial announced today is a groundbreaking study where medicinal cannabis containing little to no THC is being tested on autistic children.
-
Neurotech embarks on ground-breaking ASD trials
View More: Neurotech embarks on ground-breaking ASD trialsNeurotech International Limited (ASX:NTI) has commenced a Phase I/II open label clinical study in 20 children aged between 5-17 years with Autism Spectrum Disorder (ASD).
-
Neurotech International (ASX:NTI) secures option to Dolce Cann Global’s cannabis strains
View More: Neurotech International (ASX:NTI) secures option to Dolce Cann Global’s cannabis strainsNeurotech International (NTI) has secured an option to acquire an exclusive worldwide licence to use cannabis strains from Dolce Cann Global.
The proprietary cannabis strains will be medicinally used to treat neurological disorders such as autism, epilepsy and ADHD.